A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
|ClinicalTrials.gov Identifier: NCT00440063|
Recruitment Status : Terminated
First Posted : February 26, 2007
Last Update Posted : December 20, 2007
|Condition or disease||Intervention/treatment||Phase|
|Anemia||Drug: epoetin beta [NeoRecormon]||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Study to Compare the Safety and Effectiveness of Two Monitoring Schedules to Maintain Hemoglobin Levels and Iron Parameters in Patients With Renal Anemia Receiving NeoRecormon|
- Percentage of patients achieving target Hb within 20 weeks.
- Efficacy: % of patients exceeding upper Hb target; % who fail to reach target Hb; median time to achieve Hb target; dose of NeoRecormon required to meet target Hb concentration; % who maintain target iron parameters. Safety: AEs, SAEs.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440063
|Study Director:||Clinical Trials||Hoffmann-La Roche|